Tech Company Financing Transactions
Nectero Medical Funding Round
Nectero Medical closed a $19.5 million Series C venture capital round on 9/13/2021. Investors included Boston Scientific Corporation and private investors.
Transaction Overview
Company Name
Announced On
9/13/2021
Transaction Type
Venture Equity
Amount
$19,500,000
Round
Series C
Investors
Boston Scientific Corporation (Lead Investor)
Proceeds Purpose
Proceeds will support the company's in vivo and clinical trials to develop a potentially disruptive treatment platform that stabilizes small- to mid-sized aortic aneurysms by significantly reducing their growth rate.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
850 New Burton Rd. 201
Dover, DE 19904
USA
Dover, DE 19904
USA
Phone
Website
Email Address
Overview
Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST®, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jack Springer
Chief Financial Officer
Bryan Ziegler
General Manager
Kelvin Ning
Browse more venture capital transactions:
Prev: 9/10/2021: CaaMTech venture capital transaction
Next: 9/13/2021: Blue Note Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs